Condition: Alveolar Soft Part Sarcoma · Renal Cell Carcinoma · Triple Negative Breast Cancer · Sponsor: Canadian Cancer Trials Group
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers
This description comes directly from the study's public registry record.
Laura Pearce · 613-533-6430 · lpearce@ctg.queensu.ca
Mariam Jafri · 613-533-6430 · mjafri@ctg.queensu.ca
Always discuss trial participation with your own doctor first.
| Arthur J.E. Child Comprehensive Cancer Centre | Calgary, Alberta, Canada | Recruiting |
| University Health Network | Toronto, Ontario, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07297667